PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33163410-10	2020	Patients in the EGFR/ALK-negative/unknown cohort treated with first-line pemetrexed with platinum (PP) (15.8 months, 14.0-17.6, p<0.001) had longer mOS than those received non-PP regimens (13.1 months, 11.6-14.6).	Platinum	89-97	Moloney sarcoma oncogene	Mus musculus	148-151	
34127383-8	2021	Thirty-nine patients received platinum-based chemotherapy (PBC) and achieved a 43% objective response rate (ORR), median progression-free survival (mPFS) of 6.9 months, and median overall survival (mOS) of 31.0 months.	Platinum	30-38	Moloney sarcoma oncogene	Mus musculus	198-201	
34084103-11	2021	Compared with the docetaxel plus platinum group, the gemcitabine plus platinum group had significantly higher RR (71.4% vs. 52.6%, P < 0.05); mPFS (9.7 vs. 7.8 months, P < 0.05), and mOS (20.6 vs. 16.8 months, P < 0.01).	Platinum	33-41	Moloney sarcoma oncogene	Mus musculus	183-186	
34084103-11	2021	Compared with the docetaxel plus platinum group, the gemcitabine plus platinum group had significantly higher RR (71.4% vs. 52.6%, P < 0.05); mPFS (9.7 vs. 7.8 months, P < 0.05), and mOS (20.6 vs. 16.8 months, P < 0.01).	Platinum	70-78	Moloney sarcoma oncogene	Mus musculus	183-186	
27822420-7	2016	As representative, the G allele of rs949037 was associated with longer OS in NSCLC patients with platinum-based chemotherapy.	Platinum	97-105	Moloney sarcoma oncogene	Mus musculus	71-73	
27822420-10	2016	To conclude, polymorphisms of BCL2 gene may have an impact on the OS of platinum-based chemotherapy in NSCLC patients, which may be prognostic biomarkers of chemotherapy if validated in larger studies.	Platinum	72-80	Moloney sarcoma oncogene	Mus musculus	66-68